Lymphoma Hub cover art

Lymphoma Hub

Lymphoma Hub

By: Scientific Education Support
Listen for free

This Season's Biggest Deal | $0.99/mo for 3 months + $20 Audible bonus

Auto-renews at $8.99/mo. after 3 months - terms apply.
Summary
The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Scientific Education Support
Episodes
  • What are the key considerations when delivering 1L treatment for AS cHL and how can AEs be managed?
    Nov 17 2026

    The Lymphoma Hub was pleased to speak to Graham Collins, Oxford University Hospitals, UK. We asked, What are the key considerations when delivering 1L treatment for advanced-stage cHL and how can AEs be managed?


    In this interview, Collins discusses the considerations guiding first-line (1L) treatment selection in advanced-stage classical Hodgkin lymphoma (cHL). He explores the evolving treatment landscape, highlighting the importance of balancing treatment efficacy and toxicity, fertility considerations, and patients’ individual priorities.


    Intended for healthcare professionals. This educational resource is independently supported by Takeda Pharmaceuticals U.S.A., Inc. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    5 mins
  • How do you see tandem CAR T-cell therapies fitting into the future treatment landscape for LBCL?
    Oct 22 2026

    The Lymphoma Hub was pleased to speak with Ulrich Jäger, Medical University of Vienna, AT. We asked, How do you see tandem CAR T-cell therapies fitting into the future treatment landscape for LBCL?


    In this interview, Jäger discusses the potential role of CD19/CD20-targeted chimeric antigen receptor (CAR) T-cell therapies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). He explores the rationale for targeting both CD19 and CD20, highlights clinical data with zamtocabtagene autoleucel, and considers how tandem CAR T-cell therapies may address unmet needs in R/R LBCL. Finally, he discusses how these approaches may fit into the future treatment landscape for patients with LBCL.


    Intended for healthcare professionals. This educational resource is independently supported by Miltenyi Biomedicine. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    6 mins
  • What do the 3-year follow-up results from the STARGLO trial tell us about Glofit-GemOx in R/R DLBCL?
    Oct 8 2026

    The Lymphoma Hub was pleased to speak with Christopher P. Fox, University of Nottingham, UK. We asked, What do the 3-year follow-up results from the STARGLO trial tell us about Glofit-GemOx in R/R DLBCL?


    In this interview, Fox discusses the 3-year follow-up results from the global, randomized, phase III STARGLO trial (NCT04408638) of glofitamab (Glofit) + gemcitabine + oxaliplatin (GemOx) (n = 183) vs rituximab (R)-GemOx (n = 91) in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), recently published in Blood Advances. He also explores outcomes across clinically relevant subgroups.


    Intended for healthcare professionals. This educational resource is independently supported by Roche. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.

    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
    5 mins
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.